Some of the leaders in the field will be gathering for a special FierceBiotech panel discussion on clinical trial design and execution for cancer drugs at the upcoming annual meeting of BIO in Philadelphia on June 16.
Eleven Biotherapeutics' top pipeline prospect bombed a late-stage study in dry eye disease, failing to beat out placebo and forcing the Third Rock Ventures-founded biotech to pivot its focus.
Regeneron Pharmaceuticals is lobbying for the exome sequencing database it is building with Geisinger Health System to become the linchpin of President Obama's Precision Medicine program.
The Allen Institute for Brain Science has released an online database of neuron cell types, building blocks it thinks will lead to the creation of computer models of healthy brains. Publication of the free database marks an important, early milestone for the research program triggered by a $300 million donation from Microsoft co-founder Paul Allen in 2012.
As growing demand for lab space in Cambridge, MA, threatens to price out startups, biotech foundry Third Rock Ventures is looking to make a splash in the neighborhood to give its seedlings access to one of the industry's most vibrant innovation hubs, Beta Boston reports.
AstraZeneca is digging through the genomes of 80,000 people in search of genes linked to cardiovascular diseases and diabetes. The project is a collaboration with the Montreal Heart Institute, which will genotype 80,000 samples from AstraZeneca's biobank of blood and tissue samples.
Startup Intact Vascular expects the $38.9 million Series B it has raised will help it get its peripheral artery disease implant and delivery system into pivotal testing and through the FDA. It's been a long time since the company's $15.5 million first institutional round in September 2012.
The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche--and at least one big loser: Puma Biotechnology.
Eli Lilly has signed up to collaborate with researchers at Sanford-Burnham on a new generation of immunological drugs for diseases like lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders.
Turns out the FDA isn't the only one that's been ticked off with Orexigen since it released some early positive cardio data for obesity drug, Contrave, last March. Marketing partner Takeda is on that list, too--and earlier this week, the Japanese drugmaker went so far as to threaten to nix the pair's pact.